• 제목/요약/키워드: tumor recurrence

검색결과 1,581건 처리시간 0.033초

Isolated Supratentorial Intraventricular Recurrence of Medulloblastoma

  • Abode-Iyamah, Kingsley O.;Winslow, Nolan;Flouty, Oliver;Kirby, Patricia
    • Journal of Korean Neurosurgical Society
    • /
    • 제58권6호
    • /
    • pp.557-559
    • /
    • 2015
  • Medulloblastoma is a common pediatric tumor typically diagnosed before the age of fifteen. Initial therapy includes surgical resection and radiation of the entire neuro-axis. Recurrence is common and typically occurs within 2 years of initial diagnosis. Those fitting Collin's Law is considered tumor-free. We report a case of single supratentorial recurrence 13 years after initial diagnosis. Here we present a 22 year old male presenting 13 years after initial diagnosis with isolated septum pellucidum recurrence. He underwent complete resection of the tumor. Medulloblastoma is a common in the pediatric population. Late recurrence to the ventricular system is uncommon. Long term follow-up is recommended in these patients.

Differences in Prognostic Factors between Early and Late Recurrence Breast Cancers

  • Payandeh, Mehrdad;Sadeghi, Masoud;Sadeghi, Edris
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권15호
    • /
    • pp.6575-6579
    • /
    • 2015
  • Background: Breast cancer (BC) is the most frequent malignancy among females and is a leading cause of death of middle-aged women. Herein, we evaluated baseline characteristics for BC patients and also compared these variables across ealry and late recurrence groups. Materials and Methods: Between 1995 to 2014, among female breast cancer patients referred to our oncology clinic, eighty-six were entered into our study. All had distant metastasis. Early recurrence was defined as initial recurrence within 5 years following curative surgery irrespective of site. Likewise, late recurrence was defined as initial recurrence after 5 years. No recurrence was defined for survivors to a complete minimum of 10 years follow-up. Significant prognostic factors associated with early or late recurrence were selected according to the Akaike Information Criterion. Results: The median follow-up was 9 years (range, 1-18 years). During follow-up period, 51 recurrences occurred (distant metastasis), 31 early and 20 late. According to the site of recurrence, there were 51 distant. In this follow-up period, 19 patients died. Compared with the early recurrence group, the no recurrence group had lower lymph node involvement and more p53 positive lesions but the late recurrence group had lower tumor size. In comparison to no recurrence, p53 (odds ratio [OR] 6.94, 95% CI 1.49-32.16) was a significant prognostic factor for early recurrence within 5 years. Conclusions: Tumor size, p53 and LN metastasis are the most important risk factors for distance recurrence especially in early recurrence and also between of them, p53 is significant prognostic factor for early recurrence.

재발성 거대 세포종의 치료 (Treatment of the Recurrent Giant Cell Thmor)

  • 이상훈;김한수;장종범;이한구
    • 대한골관절종양학회지
    • /
    • 제5권1호
    • /
    • pp.23-28
    • /
    • 1999
  • Between Sep. 1986 and Mar. 1996, twenty four patients with recurrent giant cell tumor of their long bones were treated and followed up for more than two years. We applied three different modalities for treatment: curettage with bone graft, curettage and packing with polymethylmethacrylate, wide excision with or without reconstruction. During the average 51.5 months after operation(24-97 months), two of three patients who underwent curettage with bone graft showed recurrence. Patients who underwent wide excision showed no recurrence. Five of fifteen patients who underwent curettage and packing with polymethylmethacrylate showed recurrence. Four of seven who showed recurrence were treated with reapplication of curettage and packing with polymethylmethacrylate. All four patients showed no recurrence, and two of them have been followed up for more than two years. We suggest that the curettage and packing with polymethylmethacrylate is an effective treatment modality of the recurrent giant cell tumor.

  • PDF

유건종(類腱腫)의 임상적 고찰 (Clinical Investigation of Desmoid Tumors)

  • 이승구;김정만;김형민;강용구;김용식;권순용;이경태;김인
    • 대한골관절종양학회지
    • /
    • 제1권2호
    • /
    • pp.205-209
    • /
    • 1995
  • A desmoid tumor is a locally aggressive growth of connective tissue origin which infiltrates the surrounding tissue and has a marked tendency for recurrence. And so it was also called as an aggressive fibromatosis, musculofascial fibromatosis or fibrosarcoma etc. Thirteen cases of desmoid tumor was treated since 1980, and their retrospective study was done with 79 months of follow-up after initial surgical excision. The female was involved in 12 cases(one male) with the age ranged from 7-50 years, average 28 years, and seven patients in third decade. A slowly growing mass was excised on average 4 months after first notice of the mass, but their margins are not demarcated clearly in most cases. Wide excision in 12 cases was done, but wide excision and saphenous vein graft was performed in one case because of invasion of posterior tibial artery by tumor mass. The tumor was found on extraabdominal region in 8 cases(61.5%) but 5 cases in abdominal wall(38.5%). The recurrence rate was high(6/13, 46.2%), and 11 times in 6 patients were recurred(average 1.8 times), within 27 months of initial excision. Six cases of recurrence were treated with wide excision again in 3 cases, wide excision combined with radiotherapy(4,000-6,000cGy) in 4 cases and wide excision with chemotherapy in one case. During the follow-up for average 21 months after treatment, no recurrences are found. Tumor remission periods without recurrence are average 67 months in all, and 11 years in longest case. Histologically it was very mimic with fibrosarcoma but could be differentiated with Trichrome stain, and their findings are not changed after recurrence.

  • PDF

수술적으로 절제한 피부 종양 56례 (Skin and Subcutaneous Tumors Treated by Surgical Excision: A Retrospective Study in 56 Dogs)

  • 변예은;임지혜;이선태;채호철;권오경;김완희
    • 한국임상수의학회지
    • /
    • 제24권1호
    • /
    • pp.15-18
    • /
    • 2007
  • 56 dogs that had undergone surgical excision of skin lesion tumors at Veterinary Medical Teaching Hospital in Seoul National University from 2000 to 2005 were evaluated retrospectively. The ratio of cases with benign versus malignant tumor types were 1.5:1.48 cases received surgical excision alone and 8 cases received adjuvant treatments. 42 cases were followed postoperative recurrence time and survival time (25 benign, 17 malignant). 25 cases (25/42, 60%) had no recurrence after surgical excision. In malignant tumor types, 5 cases (5/17, 29%) had recurrence and the median recurrence time was 157 days, and 8 cases (8/17, 47%) died due to tumors and survival time was 125 days. In benign tumor types, only 2 cases (2/25, 8%) had recurrence and the median recurrence time was 273 days.

슬관절 주위 거대세포종의 치료 (Surgical treatment of Giant Cell Tumor in Knee Joint)

  • 배대경
    • 대한골관절종양학회지
    • /
    • 제1권1호
    • /
    • pp.1-6
    • /
    • 1995
  • Giant cell tumors are primary bone tumors originating from non-osteoblastic connective tissue. The sites of involvement were commonly distal femur, proximal tibia, proximal humerus, distal radius and others (including os calcis, ilium and sacrum). Giant cell tumor located around knee joint has been difficult to treat because of local recurrence following curettage with or without bone graft. Although primary resections reduce recurrence of the lesion, the joint function will be markedly impaired. Marginal excision was very often complicated by a loss of joint integrity since all the giant cell tumors occupy juxtaarticular positions. Techniques involving physical adjuncts(high speed burr and electric cauterization) have been used in the hope of decreasing the rate of local recurrence and avoiding the morbidity of primary resection. A meticulous clinical, radiological and histological evaluation is needed to choose the correct treatment, keeping in mind the possibility of recurrence after each treatment modality.

  • PDF

슬관절 주변에 발생한 거대세포종의 치료 - 고속 바(High-Speed Burr)와 골 시멘트를 이용한 병소 내 절제술 - (Treatment of Giant Cell Tumor Around Knee - by Intralesional Excision Using High Speed Burr and Methylmethacrylate -)

  • 박종훈;이수용;전대근;조완형;송원석;김진욱;고한상
    • 대한골관절종양학회지
    • /
    • 제11권2호
    • /
    • pp.160-167
    • /
    • 2005
  • 목적: 거대세포종은 대부분 대퇴골 원위부 및 경골 근위부에 주로 발생하며, 병소 내 소파술에서 광범위 절제술까지 다양한 수술 방법들이 시행되고있다. 저자들은 수술이 어렵고 재발율이 높은 슬관절 부위의 거대세포종 환자에서 재발율을 포함한 치료 성적을 분석하고, 재발율과 관련된 인자를 규명하고자 하였다. 대상 및 방법: 병리학적으로 확진 되고, 고속 바(high-speed burring)와 골 시멘트를 이용한 병소내 소파술을 시행 한 41예의 슬관절 주위 거대세포종 환자를 대상으로 하였다. 재발율과 기능적 평가를 통한 치료 성적을 분석하였으며, 성별, 연령, 종양의 위치, 크기, 연골 하골의 침범과 관절 내 침범 유무 그리고 Campanacci 분류에 따른 인자들과 재발율과의 상관관계를 통계적으로 분석하였다. 평균 추시 기간은 50(12~122) 개월이었다. 결과: 최종 추시 상 재발율은 17%였고, 재발시기는 평균 술 후 10개월이었다. Musculoskeletal Tumor Society (MSTS) Grading System에 의한 술 후의 기능 평가점수는 평균 27.8(93%)로 78%에서 만족스러운 기능을 보였다. 성별, 연령, 종양의 위치, 크기, 연골 하침범, 관절 내 침범, Campanacci 분류 등은 종양의 국소 재발과 통계적으로 유의한 상관 관계를 보이지 않았다. 결론: 슬관절 주변 거대세포종의 재발과 관련된 인자를 찾지는 못하였다. 수술적 치료로서 고속 바를 이용한 세심한 소파술과 골시멘트 충진술을 이용한 국소 절제술 만으로도 만족할 만한 결과 및 재발율을 얻을 수 있었다.

  • PDF

거대 세포종에서 골 소파술 및 시멘트 충전술 후의 재발 분석 (Recurrence Analysis of Giant Cell Tumor after Curettage and Cementation)

  • 한수봉;이원준;신규호
    • 대한골관절종양학회지
    • /
    • 제10권2호
    • /
    • pp.71-78
    • /
    • 2004
  • 목적: 최근 체험한 59례의 거대 세포종 중 골 소파술 및 시멘트 충전술을 시행한 37례의 재발의 특성과 이를 예방할 수 있는 방법에 대해 알아 보고자 한다. 대상 및 방법: 1995년 1월부터 2000년 3월까지 본원 정형외과에 입원하여 진단적 생검 또는 수술적 치료에 의하여 병리학적으로 거대 세포종으로 확진되고, 그 치료로 골 소파술과 Burring 후 시멘트 충전술을 시행했던 3 7례의 재발의 위치, 특성, 시기에 관하여 분석하였다. 결과: 총 37례 환자 중 일차 치료(Curettage & Cementation) 후 13례에서 재발하여 35%의 재발율을 보였다. 일차 치료 후 재발까지의 기간은 평균 16 개월로 분석되었으며, 최단 5개월에서 최장 3년 7개월이었다. 2례를 제외하고는 모두 2년 내에 재발하였다. 재발 부위는 수술적 접근 후 창(Window)을 만든 부위의 인접한 피질골에서 대부분 관찰되었으며(11례), 2례는 수술적 접근을 한 골 시멘트의 심부(골수강측)에 발생하였다. 골 소파 술 후의 시멘트 충전술은 즉각적 안정성과 빠른 재활, 재발의 조기 발견의 유용성이 있다. 또한 이론적으로 주변의 남아있는 종양세포를 사멸시킬 수 있는 장점을 가지고 있다. 수술을 시행한 실제 임상 례에서 재발의 부위가 수술시 충분한 소파가 안된 부위(Window를 작게 내어 불충분한 소파가 된 부위, 주위 해부학적 구조상 건, 인대의 기시부나 종지부로 소파가 안된 부위)에서 대부분(85%)이 재발하였다. 결론: 거대 세포종의 치료에 있어서 골 소파술과 Burring 후 시멘트 충전술이 많이 사용되고 있다. 또한 소파술 후 보조적인 치료로서 페놀, $H_2O_2$를 이용한 화학적 소작, 냉동요법, 무수 알코올 등이 소개 되었지만, 아직 그 효과가 입증된 것이 없다. 많은 경우 주위의 인대나 건의 기시부나 종지부 또는 다른 해부학적 구조로 불충분한 창(Window)으로 인해, 수술적 접근을 한 부위의 골 소파술 및 Burring 이 불완전하게 되는 경향이 발생할 수 있다. 본 연구에서 재발의 부위는 대부분(85%)에서 불충분한 개창술이 된 부위에서 발생하였다. 즉, 중요한 해부학적 구조가 있더라도 충분한 개창술과 광범위한 소파와 Burring이 재발을 방지하는 가장 중요한 요소가 되리라 사료된다. 본 연구에서 거대세포종의 재발은 대부분 2년 이내에 발생하였다. 특히 이 기간에는 철저한 추적검사를 통하여 재발에 유의해야 한다.

  • PDF

A Long-Term Survival Case of a Primary Malignant Intracerebral Nerve Sheath Tumor

  • Lee, Byung Sun;Kim, Young Gyu;Kim, Dong Ho;Lee, Mou Seop
    • Journal of Korean Neurosurgical Society
    • /
    • 제54권3호
    • /
    • pp.261-264
    • /
    • 2013
  • We report a long-term survival case of a primary malignant intracerebral nerve sheath tumor (MINST) occurring in the right frontal lobe of a 13-year old boy. After the gross total resection (GTR), we have performed radiation therapy but it recurred 50 months after the surgery, so the second GTR was performed. Later, second tumor recurrence was found 4 months after the second surgery. Subsequently the third GTR, radiotherapy, and chemotherapy were carried out. At present, the patient has been remaining alive for 77 months without evidence of tumor recurrence. According to the previous reports, the primary MINST is very rare : there are only 8 cases reported. It is also a fast-growing, invasive tumor with poor outcome. This is the first case that had no recurrence for 50 months after the surgery among the reported cases that had been followed up for more than 5 years. It is supposed that a period of recurrence free survival after GTR and low mitotic activity are associated with the patient's prognosis. A GTR followed by adjuvant radiation therapy and chemotherapy will be recommended to patients of MINST.

Breast Cancer Recurrence According to Molecular Subtype

  • Shim, Hee Jin;Kim, Sung Hun;Kang, Bong Joo;Choi, Byung Gil;Kim, Hyeon Sook;Cha, Eun Suk;Song, Byung Joo
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권14호
    • /
    • pp.5539-5544
    • /
    • 2014
  • Background: To evaluate the location of tumor relapse and imaging modality for detection according to the breast cancer subtype: luminal A, luminal B, HER2 positive luminal B, nonluminal HER2 positive, and triple negative. Materials and Methods: A total of 1244 patients with breast cancer with known estrogen receptor (ER), progesterone receptor (PR), Ki-67 and human epidermal growth factor receptor 2 (HER2), who underwent breast surgery from 2009 to 2012 were analyzed. Patients were classified into the following categories: luminal A (n=458), luminal B (n=241), HER2 positive luminal B (n=227), nonluminal HER2 positive (n=145) and triple negative (n=173). A total of 105 cases of relapse were detected in 102 patients: locoregional recurrence (n=46), recurrence in the contralateral breast (n=28) and distant metastasis (n=31). Comparison of proportions was used to determine the difference between subtypes. Results: Relapse rates by subtypes are as follows: luminal A 23 of 458 (5.02%), luminal B 19 of 241(7.88%), HER2 positive luminal B 15 of 227 (6.61%), nonluminal HER2 postive 19 of 145 (13.10%) and triple negative 29 of 173(16.76%). Luminal A tumors had the lowest rate of recurrence and had significantly lower recurrence rate in comparison with nonluminal HER2 postive (p=0.0017) and triple negative subtypes (p<0.0001). Compared with all other subtypes except nonluminal HER2 positive, triple negative tumors had the highest rate of tumor recurrence (p<0.01). Triple negatives were most likely to develop contralateral recurrence against all subtypes (p<0.05). Detection rate of locoregional and contralateral tumor recurrence were 28.3% on mammography (n=17/60). Conclusions: Luminal A tumors are associated with a low risk of recurrence while triple negative lesions have a high risk. In case of triple negative tumors, the contralateral breast has much more recurrence as compared with all other subtype. In terms of detection rates, breast USG was the best modality for detecting tumor recurrence, compared with other modalities (p<0.05). Subtyping of breast tumors using a molecular gene expression panel can identify patients who have increased risk of recurrence and allow prediction of locations of tumor recurrence for each subtype.